| HOME >> BIOLOGY >> TECHNOLOGY |
ST. LOUIS, Feb. 19 /PRNewswire-FirstCall/ -- Sigma-Aldrich(R) (Nasdaq: SIAL) is pleased to announce that Helge Bastian, Ph.D, has joined Sigma-Aldrich as Vice President of Global Marketing for the Research Biotech business unit. Dr. Bastian will be responsible for our strategic and commercial marketing efforts to drive top line growth through the identification, development and launch of innovative products into the life science market. Dr. Bastian has over 15 years of international leadership experience in the molecular biology and diagnostics, biotechnology, drug development and pharmaceutical manufacturing industry.
He was previously executive vice president of the Life Science Services business unit at SGS, a leading inspection, verification and certification company, and member of the senior executive management team in Geneva, Switzerland. Helge held various management positions at QIAGEN for more than 11 years, including Vice President of Molecular Diagnostics, Vice President of Global Strategic Marketing and Vice President of PreAnalytiX, and member of QIAGEN's executive steering committee and PreAnalytiXs management committee.
Helge studied biology at the Universities in Kiel, Gottingen, and Munich, Germany, and holds a diploma in biology (focus area of biochemistry) and a Ph.D. in molecular biology conducted at the Max-Planck Institute for Biophysical Chemistry from the University of Gottingen, Germany. He is an alumnus from the Max-Planck Network and the Columbia Business School.
About Sigma-Aldrich: Sigma-Aldrich is a leading Life Science and High
Technology company. Our biochemical and organic chemical products and kits
are used in scientific and genomic research, biotechnology, pharmaceutical
development, the diagnosis of disease and as key components in
pharmaceutical and other high technology manufacturing. We have customers
in life science companies, university and government institutions,
hospitals, and in industry. Over
'/>"/>
| SOURCE Sigma-Aldrich Copyright©2008 PR Newswire. All rights reserved |